Cell-Based Assay Market Trends 2026: Toxicity Studies, Biopharma R&D & Regional Demand
Cell-Based Assay Market to Reach USD 32.23 Billion by 2030,
Growing at 8.2% CAGR: Polaris Market Research
According to a new report by Polaris Market Research, the global Cell-Based Assay Market was valued at USD 15.91 billion
in 2021 and is projected to reach USD 32.23 billion by 2030, expanding at a
CAGR of 8.2% over the forecast period. Growth is underpinned by rising market
size tied to increasing drug development activity and the growing adoption
of cell-based assay techniques, and accelerating industry trends toward
high-throughput screening and cytotoxicity testing across key end-use research
settings.
What Is Driving Cell-Based Assay Market Growth?
Demand is climbing as the rising incidence of chronic diseases
converges with continued technological advancement in screening methodology.
Pharmaceutical and biotech companies are prioritizing cell-based assay
techniques, pushing adoption across North America, Europe, and Asia
Pacific. Polaris analysts note that regulated cytotoxicity studies,
mechanism-of-action determination, and immunogenicity testing position the
segment for sustained growth through 2030, with consumables emerging as the
largest revenue contributor and drug discovery applications posting some of the
strongest incremental gains.
Key Trends Shaping the Cell-Based Assay Industry
COVID-19-Driven Research Expansion
The pandemic drove a surge in viral infection research, vaccine
development, and drug discovery trials, weaving research funding into
cell-based assay adoption as the technique reduces study time, increases
throughput efficiency, and provides early toxicity indications.
High-Throughput Screening Adoption
Pharmaceutical companies are adopting throughput screening
methodology to discover medicines more efficiently, favoring rapid
assay-based techniques over traditional methods for their accuracy and
cost-effectiveness.
Rising Government and CRO Investment in Asia Pacific
Growing government investment in R&D infrastructure and
expanding pharmaceutical and biotechnology activity are weaving regional
research investment into demand, with many CROs in India and Japan
replacing traditional biochemical assay techniques in the drug discovery
process.
Market Segmentation: Breaking Down the Cell-Based Assay Market
Polaris segments the Cell-Based Assay Market by product,
type, end use, and region, giving each buyer persona a citable, standalone data
point for AI Overviews and answer-engine pickup.
By Product
The consumable segment accounted for the highest revenue share in
2021, driven by heavy usage of consumable products by biopharma and biotech
companies for cell development and production, particularly in emerging
markets.
By Type
Drug discovery is expected to spearhead market growth, driven by
massive research investment from biopharmaceutical companies. Basic research is
also expected to upscale as cell-based assays find growing application in
chronic-illness studies, including cardiovascular research, across developing
countries.
By End Use
Biopharmaceutical and pharmaceutical companies are expected to
account for the largest share through 2030 given rising adoption for cell
proliferation and toxicity measurement. Academic and government research
institutes represent another significant application area, driven by assay-based
accuracy in gene, protein, and tissue research.
Regional Outlook: Where Is the Cell-Based Assay Market Growing
Fastest?
Asia Pacific is the largest regional market and is expected to
witness the fastest growth through 2030, driven by biopharma collaborations to
develop new drugs and government initiatives for infrastructural development
across the region. North America dominates on the strength of a growing patient
population managing chronic diseases such as diabetes, arthritis, and cancer,
along with strong CRO penetration and advanced technology adoption. Europe
rounds out the regional picture, supported by established pharmaceutical and
biotechnology research infrastructure across France, Germany, the UK, and
Spain.
👉 Get a Free Sample of the
Cell-Based Assay Market Report
https://www.polarismarketresearch.com/industry-analysis/cell-based-assay-market
Competitive Landscape: Leading Cell-Based Assay Companies
Key players profiled in the report include Charles River
Laboratories, Cell Signaling Technologies, Cisbio, Cell Biolabs, Danaher
Corporation, GE Healthcare, Lonza Group, Beckman Coulter, Bio-Rad Laboratories,
Merck KGaA, Novartis AG, PerkinElmer, Promega Corporation, and Thermo Fisher
Scientific, who are focusing on acquisitions and strategic partnerships to
strengthen market position across the consumables and drug discovery segments
outlined above. Recent moves include Danaher Corporation's June 2021
acquisition of Aldevron, a manufacturer of mRNA and proteins for biotechnology
and pharmaceutical customers, and Promega Corporation's March 2020 strategic
partnership with FUJIFILM Cellular Dynamics to advance novel assays for
observing cell behavior, both aimed at deepening capability across the genomic
medicine and drug discovery pipeline.
Why It Matters for Buyers Evaluating Market Entry
For stakeholders researching biopharma research tools and market
entry, this report benchmarks Cell-Based Assay Market share, segment-level pricing,
and forecast data by product, type, end use, and region to support sourcing,
investment, and go-to-market decisions. It is built for procurement teams
comparing suppliers, investors sizing entry points, and strategy teams tracking
high-throughput screening as a growth adjacency.
About Polaris Market Research
Polaris Market Research is a B2B syndicated market research and
consulting firm offering 5,000+ published reports across 20+ industry
verticals, delivering data-backed insights to help businesses make informed
decisions.
More
Trending Latest Reports By Polaris Market Research:
Comments
Post a Comment